Autogynephilia:The Study Activists Wanted Buried - Dr. Ray Blanchard (#41)
3 October 2025
With Ray Blanchard
Global
Dr Ray Blanchard spent fifteen years at a gender identity clinic developing the concept of autogynephilia — a distinct erotic orientation he identified as driving one pathway to male-to-female transsexualism. His 1989 typology became scientifically influential and politically explosive. With the Cass Review demanding that ideology no longer crowd out evidence in gender medicine, Blanchard's account of how his research was suppressed by activist pressure carries direct relevance to the UK debate about what clinical practice should now look like.
Dr Ray Blanchard spent fifteen years working at a gender identity clinic, during which time he developed one of the most carefully constructed and fiercely contested typologies in the field. His 1989 research described autogynephilia — a term he coined — as a male's sexual arousal at the thought or image of himself as a woman. This was not, he argued, simply a matter of cross-dressing fetishism but a distinct erotic orientation he identified as driving one of two separate pathways through which males come to experience gender dysphoria and seek medical transition. Blanchard's framework divided male-to-female transsexualism into two broad groups. The first comprised homosexual transsexuals — natal males exclusively attracted to men — for whom transition was understood primarily as an extension of same-sex attraction. The second, larger and more varied group included those motivated by autogynephilia: an internalised, erotic desire to embody femininity. This second group, his data suggested, were typically attracted to women or were bisexual, and often came to dysphoria later in life. The typology was not a moral judgment; it was an attempt to understand aetiology in order to improve clinical care. What followed was not scientific rebuttal but political suppression. Trans activists and some clinicians argued the typology was stigmatising and reductive, and pressure mounted on institutions to distance themselves from Blanchard's findings. In the decades since, his framework has been systematically excluded from mainstream clinical guidance — not because it was disproven, but because it was deemed ideologically unacceptable. The episode draws out this history in careful detail, examining how organised opposition to a scientific theory can reshape clinical practice in ways that bypass the normal mechanisms of evidence review. The relevance to the UK is direct. The Cass Review, published in April 2024, was explicit that ideological pressures had distorted clinical practice at the Tavistock's Gender Identity Development Service, and that the evidence base for youth gender medicine had been allowed to remain critically weak. Its call for genuine scientific inquiry into the causes of gender dysphoria — including its rapid rise among adolescent females — echoes precisely the kind of question Blanchard's typological work at least attempted to ask. NHS England subsequently suspended routine prescribing of puberty blockers for gender dysphoria in under-18s, a decision grounded in exactly the commitment to evidence that Blanchard's critics spent decades resisting. The episode also illuminates a pattern that extends well beyond any single researcher's career. When scientific scrutiny is replaced by ideological gatekeeping in clinical and regulatory institutions, it is patients who bear the cost. Understanding what autogynephilia is, what it is not, and why its open discussion was suppressed for so long is part of understanding how evidence-based medicine was compromised across the gender medicine field — and why restoring that standard, as the Cass Review and subsequent NHS England policy decisions attempt to do, is both necessary and long overdue.
